A Phase 2 Open-Label Study of the Efficacy of TPI 287 in Patients With Glioblastoma Multiforme That Has Recurred or Progressed Following Prior Therapy With Radiation Plus Temozolomide.
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2016
At a glance
- Drugs TPI 287 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Aug 2012 Planned end date changed from 1 Apr 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 22 Oct 2011 New source identified and integrated (M.D. Anderson Cancer Center).